Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Oxford based CEO’ operating in the Life Science space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Emma Sceats
CEO of Isogenica
Dr Sceats joined CN Bio Innovations in 2010 as Commercial Manager to spearhead the organisation’s sales, marketing and business development activities. She has led sales and partnering initiatives with major pharmaceutical organisations and overseen academic research and licensing programs, including with the Massachusetts Institute of Technology (MIT) that have led to the development of the company’s leading products. Dr Sceats was promoted to Chief Operating Officer in May 2013 with responsibility for the day-to-day running of the company, focussing on delivering the objectives of company investors. Dr Sceats holds degrees from Oxford and Bristol Universities (UK) and the Massachusetts Institute of Technology, where she studied Chemistry. Her previous roles include working as a research scientist at E.I. DuPont de Nemours (Wilmington, DE, USA) and in intellectual property management and licensing for the University of Oxford.
Follow Emma Sceats:
About Isogenica: Isogenica operates a range of discovery platforms supported by state-of-the-art methodologies for identifying antibody and peptide ligands.
_______
Connor Campbell
Founder and CEO of Osler Diagnostics
Follow Connor Campbell:
About Osler Diagnostics: Lab-quality diagnostics for anyone, anywhere, at any time.
Bo Jing
CEO of ONI
Follow Bo Jing:
About ONI: ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers.
Martin-Immanuel Bittner
Co-Founder & CEO of Arctoris
Martin-Immanuel Bittner MD DPhil is a clinician-scientist and life sciences entrepreneur. He is a Rhodes scholar, an active member of several leading cancer research organisations, and an elected member of the Young Academy of the German National Academy of Sciences. Martin is a Co-Founder & CEO of Arctoris, the world’s first fully automated drug discovery platform.
Follow Martin-Immanuel Bittner:
About Arctoris: Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Peter Donnelly
Chief Executive Officer of Genomics
Peter Donnelly is Director of the Wellcome Trust Centre for Human Genetics and Professor of Statistical Science at the University of Oxford, and a founder and director of Genomics plc, a fast-growing company in the genome analytics space. He has played a leading role in many of the major projects and developments at the interface between genetics, healthcare, and clinical medicine, including the HapMap project, the Wellcome Trust Case Control consortia, and WGS500, one of the studies pioneering whole genome sequencing in clinical medicine.
Follow Peter Donnelly:
About Genomics, University of Oxford: Genomics plc aiming to lead the genomic transformation of healthcare.
Ann Kramer
CEO of The Electrospinning Company
Ann Kramer is CEO of The Electrospinning Company: a biomaterial platform company with applications in regenerative medicine and medical device markets.
Ann graduated from the University of Cambridge with a degree in Natural Sciences and joined ICI Agrochemicals. Over almost 20 years with ICI, Zeneca and Syngenta she gained experience across the business including in research, sales, business development and M&A, with roles in the UK, USA and Switzerland. She managed the development of genetically modified food business streams in fresh produce crops. Since 2006 she has worked in the SME sector in the UK as Head of Business development for Oxitec Ltd. (acquired by Intrexon in 2015), COO of Immunocore Ltd. and CEO of Biosyntha Ltd. She joined The Electrospinning Company as CEO in 2012.
Follow Ann Kramer:
About The Electrospinning Company: The Electrospinning Company is a provider of electrospun nanofibre innovations, developing solutions to industrial challenges.
Mark Larkin
CEO and Founder of Vitaccess
Mark Larkin founded Vitaccess in 2017, after more than 15 years in consultancy, with the aims of harnessing the power of digital technology to better represent the voice of patients in drug development and market access. Mark has a BA, MA and PhD from the University of Cambridge, UK.
Follow Mark Larkin:
About Vitaccess: Digital healthcare company providing biopharma clients with real-time insights into patients’ lives via innovative global studies
Sumi Biswas
Co-founder, Chief Executive Officer, and Chief Scientific Officer of SpyBiotech
Sumi Biswas is the Co-Founder, Chief Executive Officer, and Chief Scientific Officer of Spybiotech.
Follow Sumi Biswas:
About SpyBiotech: SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.
David Hughes
CEO of CN Bio Innovations
Dr Hughes joined CN Bio Innovations in 2010 as Head of Engineering, was promoted to Technical Director in 2013 with responsibility for the management of all in-house and collaborative research and development programmes and the contract research services business. Dr Hughes was subsequently promoted to Chief Technology Officer in July 2014 with responsibility for managing the technical programs with the company’s academic and industrial partners. and, in 2018, he was promoted to CEO. During his career at CN Bio, he has secured and overseen the successful delivery of government and pharmaceutical research contracts and research grants totalling more than £2Mi.
Follow David Hughes:
About CN Bio Innovations: CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases.
David Hughes
CEO of CN Bio Innovations
Dr Hughes joined CN Bio Innovations in 2010 as Head of Engineering, was promoted to Technical Director in 2013 with responsibility for the management of all in-house and collaborative research and development programmes and the contract research services business. Dr Hughes was subsequently promoted to Chief Technology Officer in July 2014 with responsibility for managing the technical programs with the company’s academic and industrial partners. and, in 2018, he was promoted to CEO. During his career at CN Bio, he has secured and overseen the successful delivery of government and pharmaceutical research contracts and research grants totalling more than £2Mi.
Follow David Hughes:
About CN Bio Innovations: CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases.
